The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: Clinical risk, immunological gaps, and therapeutic options

Clinical Infectious Diseases

Volumn 48, Issue 3, 2009, Pages 328-337

  Gazzola, Lidia ^a   Tincati, Camilla ^a   Bellistrì, Giusi Maria ^a   Monforte, Antonella D'Arminio ^a   Marchetti, Giulia ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 7; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE MARROW; CD4 LYMPHOCYTE COUNT; DEATH; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS REPLICATION; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; HUMAN;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 58749087048     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/595851     Document Type: Review

References (103)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998; 351:228-30.
3. Autran B, Carcelain G, Li TS, et al. Restoration of the immune system with anti-retroviral therapy. Immunol Lett 1999; 66:207-11.
4. Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998; 12:745-50.
5. + cell counts after successful virologic suppression. Clin Infect Dis 2002; 35:1005-9.
6. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-65.
7. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41:361-72.
8. d'Arminio Monforte A, Testori V, Adorni F, et al. CD4 cell counts at the third month of HAART may predict clinical failure. AIDS 1999;13:1669-76.
9. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-10.
10. Moore DM, Hogg RS, Yip B, et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 2005; 40:288-93.
11. Nicastri E, Chiesi A, Angeletti C, et al. Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. J Med Virol 2005; 76:153-60.
12. Gutiérrez F, Padilla S, Masia M, et al. Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr HIV Res 2008; 6:100-7.
13. Tan R, Westfall AO, Willig JH, et al. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47:553-8.
14. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Washington, DC: Department of Health and Human Services, 2008.
15. 3. J Acquir Immune Defic Syndr 2007; 44:179-87.
16. Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002; 16:359-67.
17. Florence E, Lundgren J, Dreezen C, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003; 4:255-62.
18. Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001; 183:1290-4.
19. Lederman MM, McKinnis R, Kelleher D, et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS 2000; 14:2635-42.
20. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination antiretroviral therapy: variation by age. AIDS 2008; 22:1463-73.
21. Phillips A. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004; 18:51-8.
22. Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis 2005; 41:713-20.
23. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. J Infect Dis 1998; 178:1189-92.
24. Laskus T, Radkowski M, Piasek A, et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000; 181:442-8.
25. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-5.
26. De Luca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162:2125-32.
27. Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002; 16:1915-23.
28. Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS 2006; 20:1171-9.
29. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35:261-8.
30. Wood E, Montaner JS, Yip B, et al. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antivir Ther 2004; 9:229-35.
31. + cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441-6.
32. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-29.
33. + cell recovery during suppressive highly active antiretroviral therapy. Clin Infect Dis 2008; 46:149-50.
34. Spritzler J, Mildvan D, Russo A, et al. Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:551-8.
35. + cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 2005; 191:1670-9.
36. Moses A, Nelson J, Bagby GC Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood 1998; 91:1479-95.
37. Isgro A, Aiuti A, Mezzaroma I, et al. Improvement of interleukin 2 production, clonogenic capability and restoration of stromal cell function in human immunodeficiency virus-type-1 patients after highly active antiretroviral therapy. Br J Haematol 2002; 118:864-74.
38. Isgro A, Aiuti A, Leti W, et al. Immunodysregulation of HIV disease at bone marrow level. Autoimmun Rev 2005; 4:486-90.
39. + T-cells despite suppression of HIV replication under HAART. AIDS Rev 2006; 8:88-97.
40. + T cell counts despite viral suppression during HAART. Clin Infect Dis 2008; 46:1902-10.
41. Badolato R. Immunological nonresponse to highly active antiretroviral therapy in HIV-infected subjects: is the bone marrow impairment causing CD4 lymphopenia? Clin Infect Dis 2008; 46:1911-2.
42. Kolte L, Dreves AM, Ersboll AK, et al. Association between larger thymic size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J Infect Dis 2002; 185:1578-85.
43. Franco JM, Rubio A, Martinez-Moya M, et al. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood 2002; 99:3702-6.
44. Fry TJ, Mackall CL. What limits immune reconstitution in HIV infection? Divergent tools converge on thymic function. AIDS 2001; 15:1881-2.
45. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396:690-5.
46. Teixeira L, Valdez H, McCune J, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001; 15:1749-56.
47. Marziali M, De Santis W, Carello R, et al. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS 2006; 20:2033-41.
48. Marchetti G, Gori A, Casabianca A, et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 2006; 20:1727-36.
49. Fry T, Connick E, Falloon J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood 2001; 97:2983-90.
50. Napolitano L, Grant R, Deeks S, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nature Medicine 2001; 7:73-9.
51. Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005; 174:6571-6.
52. Valdez H, Connick E, Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16:1859-66.
53. + T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-43.
54. Pitrak DL, Bolanos J, Hershow R and Novak RM. Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis. AIDS 2001; 15:1317-9.
55. Ostrowski SR, Katzenstein TL, Thim PT, Pedersen BK, Gerstoft J, Ullum H. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis 2005; 191:348-57.
56. + T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis 2002; 185:1672-6.
57. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006; 7:235-9.
58. Douek D. HIV disease progression: immune activation, microbes, and a leaky gut. Top HIV Med 2007; 15:114-7.
59. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71.
60. + T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 2008; 22:2035-8.
61. Guadalupe M, Sankaran S, George MD, et al. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 2006; 80:8236-47.
62. + T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77:11708-17.
63. Estes J, Baker JV, Brenchley JM, et al. Collagen deposition limits immune reconstitution in the gut. J Infect Dis 2008; 198:456-64.
64. Paiardini M, Frank I, Pandrea I, Apetrei C, Silvestri G. Mucosal immune dysfunction in AIDS pathogenesis. AIDS Rev 2008; 10:36-46.
65. Read SW, Sereti I. HIV infection and the gut: scarred for life? J Infect Dis 2008; 198:453-5.
66. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6:345-52.
67. Haas DW, Geraghty DE, Andersen J, et al. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: an AIDS Clinical Trials Group study. J Infect Dis 2006; 194:1098-107.
68. O'Brien TR, McDermott DH, Ioannidis JP, et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 2000; 14:821-6.
69. Puissant B, Roubinet F, Massip P, et al. Analysis of CCR5, CCR2, CX3CR1, and SDF1 polymorphisms in HIV-positive treated patients: impact on response to HAART and on peripheral T lymphocyte counts. AIDS Res Hum Retroviruses 2006; 22:153-62.
70. Rauch A, Nolan D, Furrer H, et al. HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clin Infect Dis 2008; 46:1921-5.
71. Arnò A, Ruiz L, Juan M, et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μL CD4 T cells and undetectable plasma virus load. J Infect Dis 1999; 180:56-60.
72. Marchetti G, Meroni L, Varchetta S, et al. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis 2002; 186:606-16.
73. Katlama C, Carcelain G, Duvivier C, et al. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study-ANRS 082. AIDS 2002; 16:2027-34.
74. Levy Y, Durier C, Krzysiek R, et al. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 2003; 17:343-51.
75. Sullivan A, Hardy G, Nelson M, Gotch F, Gazzard B, Imami N. Interleukin-2 associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapy. AIDS 2003; 17:628-9.
76. Blattman J, Grayson J, Wherry E, Kaech S, Smith K, Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nature Medicine 2003; 9:540-7.
77. Marchetti G, Franzetti F, Gori A. Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap? J Antimicrob Chemother 2005; 55:401-9.
78. Farel CE, Chaitt DG, Hahn BK, et al. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 2004; 103:3282-6.
79. Sereti I, Aga E, Spritzler J, et al.; ACTG 5214 team. rhIL7 in HIV-1-infected subjects with CD4 T-cell count >100 cells/μL and viral load <50,000 copies/mL: results from a randomized, placebo-controlled, double-blinded study (ACTG5214) [abstract 128]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007:112.
80. Levy Y, Weiss L, Viard JP, et al. Repeated r-hIL-7 doses improve T-cell recovery in HIV-1-infected patients enrolled in a phase i/ii multicentric study [abstract 127]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007:112.
81. Levy Y, Weiss L, Goujard C, et al. Sustained immunological efficacy of repeated r-hIL-7 doses in HIV-1-infected patients: long-term follow-up of a phase i/ii multicentric study [abstract 708]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2008:325.
82. Chougnet CA, Shearer GM. Regulatory T cells (Treg) and HIV/AIDS: summary of the September 7-8, 2006 workshop. AIDS Res Hum Retroviruses 2007; 23:945-52.
83. Sereti I, Imamichi H, Natarajan V, et al. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005; 115:1839-47.
84. + T-regulatory cells. J Immunother 2006; 29:313-9.
85. MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368:2125-35.
86. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-106.
87. Caron M, Auclairt M, Vissian A, Vigouroux C, Capeau J. Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Antivir Ther 2008; 13:27-38.
88. + cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Clin Infect Dis 2000; 30:392-4.
89. Giorgi JV, Majchrowicz MA, Johnson TD, Hultin P, Matud J, Detels R. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS 1998; 12:1833-44.
90. Hejdeman B, Lenkei R, Leandersson AC, et al. Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection. AIDS Res Hum Retroviruses 2001; 17:277-86.
91. Smith D, Zaunders J, Kauffman G, et al. Greater suppression of CD8 activation with 4 vs. 3 drugs in early stages of primary HIV infection (PHI) despite similar virological decay rates [abstract 61]. In: Program and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment (Buenos Aires, Argentina) Geneva: International AIDS Society, 2001:101.
92. Havlir DV, Strain MC, Clerici M, et al. Productive infectionmaintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77:11212-9.
93. Bourgarit A, Lascoux C, Palmer P, et al. First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases. AIDS 2006; 20:471-3.
94. + cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations. J Med Virol 2008; 80:937-41.
95. Watson C, Jenkinson S, Kazmierski W, Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 2005; 67:1268-82.
96. Wilkin T, Ribaudo H, Gulick R. The relationship of CCR5 inhibitors to CD4 cell count changes: a meta-analysis of recent clinical trials in treatment-experienced subjects [abstract 800]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2008:362.
97. Hughes R, Sabin C, Sterne JAC,. Long-term trends in CD4 counts in patients starting HAART: UK CHIC study [abstract P18.4/04/BPD]. In: Program and abstracts of the 11th European AIDS Conference (Madrid). European AIDS Clinical Society, 2007:137.
98. Coull JJ, Turner D, Melby T, Betts MR, Lanier R, Margolis DM. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2001; 26:423-34.
99. Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002; 109:681-8.
100. Lederman MM, Smeaton L, Smith KY, et al. Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. J Infect Dis 2006; 194:1677-85.
101. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. Aids 2004; 18:257-64.
102. Gori A, Rossi M, Trabattoni D, et al. Tumor necrosis factor-α increased production during thalidomide treatment in patients with tuberculosis and HIV coinfection. J Infect Dis 2000; 182:639-40.
103. De Maria A. Discordant responses to HAART in HIV-1 patients: the need to focus on intervention. Expert Rev Anti Infect Ther 2007; 5:523-7.